Author Archives for

AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million

IRVINE, Calif., January 10, 2023 – AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple…

AEON Biopharma Completes Enrollment in Phase 2 Trial 

of ABP-450 for Preventive Treatment of Episodic Migrain – Topline data expected to be announced in 2H 2023 – – Topline data from the Company’s Phase 2 trial in preventive…

Overview: Proposed Merger Agreement with Priveterra Acquisition Corp. (Nasdaq: PMGM)

Download the full presentation

AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology 

AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology  – Positive topline data…

A Transformation of the Healthcare Experience

Empowering patients, enabling specialists, and driving innovation in the health and wellness industry.

LEARN MORE

AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia

– Phase 2 trial met primary and secondary endpoints with statistical significance in reducing signs and symptoms associated with cervical dystonia (CD) in adults – – All three dosing arms…

AEON Biopharma Raises $30 Million from Insiders

Brings Total Capital Raised Since December 2021 to $54.5 Million Irvine, Calif., August 3, 2022 – AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on…

AEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical Dystonia

Topline data expected to be announced in the second half of 2022 Newport Beach, Calif., April 11, 2022 – AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical…

AEON Biopharma Announces the Appointment of Alex Wilson as General Counsel

Newport Beach, Calif., August 11, 2021 – AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic…